[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.183.113. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Comment & Response
December 2016

Modeling the Effects of Priming With the Whole-Cell Bordetella Pertussis Vaccine

Author Affiliations
  • 1Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, University of Western Australia, West Perth, Western Australia
  • 2National Centre for Immunisation Research and Surveillance, Westmead, Australia
  • 3Discipline of Child and Adolescent Health and School of Public Health, University of Sydney, Sydney, Australia
  • 4The Children’s Hospital, Westmead, Australia
JAMA Pediatr. 2016;170(12):1228-1229. doi:10.1001/jamapediatrics.2016.2603

To the Editor The modeling study of DeAngelis et al1 suggested that substitution of 1 dose of whole-cell pertussis vaccine for the first dose of acellular vaccine at age 6 to 8 weeks would result in at least a 91% reduction in the incidence of pertussis. As noted in the accompanying editorial, the validity of these findings relies on both explicit and implicit assumptions within the model structure and its parameters. We go further to say that such a profound effect on pertussis disease and transmission seems inherently unlikely and that implementation barriers are understated.

×